1. Home
  2. PRLD vs WNW Comparison

PRLD vs WNW Comparison

Compare PRLD & WNW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRLD
  • WNW
  • Stock Information
  • Founded
  • PRLD 2016
  • WNW 2015
  • Country
  • PRLD United States
  • WNW China
  • Employees
  • PRLD N/A
  • WNW N/A
  • Industry
  • PRLD Medicinal Chemicals and Botanical Products
  • WNW Catalog/Specialty Distribution
  • Sector
  • PRLD Health Care
  • WNW Consumer Discretionary
  • Exchange
  • PRLD Nasdaq
  • WNW Nasdaq
  • Market Cap
  • PRLD 73.7M
  • WNW 145.7M
  • IPO Year
  • PRLD 2020
  • WNW 2020
  • Fundamental
  • Price
  • PRLD $1.39
  • WNW $2.78
  • Analyst Decision
  • PRLD Strong Buy
  • WNW
  • Analyst Count
  • PRLD 2
  • WNW 0
  • Target Price
  • PRLD $4.50
  • WNW N/A
  • AVG Volume (30 Days)
  • PRLD 783.6K
  • WNW 1.6M
  • Earning Date
  • PRLD 02-13-2025
  • WNW 01-14-2025
  • Dividend Yield
  • PRLD N/A
  • WNW N/A
  • EPS Growth
  • PRLD N/A
  • WNW N/A
  • EPS
  • PRLD N/A
  • WNW N/A
  • Revenue
  • PRLD $3,000,000.00
  • WNW $380,345.00
  • Revenue This Year
  • PRLD N/A
  • WNW N/A
  • Revenue Next Year
  • PRLD N/A
  • WNW N/A
  • P/E Ratio
  • PRLD N/A
  • WNW N/A
  • Revenue Growth
  • PRLD N/A
  • WNW N/A
  • 52 Week Low
  • PRLD $0.80
  • WNW $0.71
  • 52 Week High
  • PRLD $6.80
  • WNW $11.11
  • Technical
  • Relative Strength Index (RSI)
  • PRLD 60.84
  • WNW 72.05
  • Support Level
  • PRLD $1.12
  • WNW $1.64
  • Resistance Level
  • PRLD $1.48
  • WNW $3.02
  • Average True Range (ATR)
  • PRLD 0.18
  • WNW 0.54
  • MACD
  • PRLD 0.05
  • WNW 0.08
  • Stochastic Oscillator
  • PRLD 74.78
  • WNW 67.05

About PRLD Prelude Therapeutics Incorporated

Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.

About WNW Meiwu Technology Company Limited

Meiwu Technology Co Ltd operates as an online food retail store and franchise restaurants in China. The products offered include green food, organic food, intangible cultural heritage food products, agricultural products bearing geographical indications, and pollution-free products. It operates in three segments: Clean Food Platform; Restaurant; and Others. The company generates the majority of its revenue from Technical services.

Share on Social Networks: